Moderna, Inc. (MRNA)
Nasdaq · Cambridge, Massachusetts, USA · Founded 2010 · CEO Stéphane Bancel
Valuation summary
Fair value is not meaningful for this company — the model produces a negative equity value. Rated Sell.
| Fair value per share | N/M |
| Current share price | $199.33 |
| Upside / downside | -102.1% |
| Bear case | N/M |
| Bull case | N/M |
| Discount rate (WACC) | 13.9% |
| Terminal growth | 3.00% |
| Market capitalisation | $80B |
| EV / Sales | 35.0x |
About Moderna, Inc.
Founded in 2010 to develop messenger RNA therapeutics, an approach with no approved products until COVID-19 vaccines validated it at extraordinary speed. Stéphane Bancel has been CEO since 2011. Revenue collapsed from pandemic peaks and Moderna is now spending heavily to prove mRNA works beyond COVID — in RSV, influenza, and most importantly individualised cancer vaccines.
Investment case
- The mRNA platform allows far faster development cycles than conventional biologics.
- Individualised neoantigen therapy intismeran, with Merck's Keytruda, met its primary recurrence-free survival endpoint in the Phase 3 INTerpath-001 melanoma trial in August 2026.
- Cash plus $2.6 billion of convertible notes raised in August 2026 funds oncology expansion and several more years of development.
Key risks
- Deeply lossmaking, with revenue far below the cost base built during the pandemic.
- COVID vaccine demand continues to decline and is now seasonal at best.
- After the August 2026 melanoma readout the valuation assumes regulatory approval and commercial success for cancer vaccines that have not yet been filed.
Recent developments
- 2026-10-01 · Nasdaq said Moderna will join the Nasdaq-100 on 9 October 2026, replacing Warner Bros. Discovery. source
- 2026-08-28 · Moderna priced an upsized $2.6bn zero-coupon convertible due 2032, conversion price about $210.58, a 47.5% premium to $142.77. source
- 2026-08-19 · Phase 3 INTerpath-001 of intismeran plus Keytruda in resected melanoma met its recurrence-free survival primary endpoint at an interim analysis. source
- 2026-08-05 · FDA granted full approval to Moderna's mRNA flu vaccine mFLUSIVA for adults aged 50 and older. source
Revenue by segment
| COVID-19 Vaccines | 62% |
| RSV & Flu | 20% |
| Other & Collaborations | 18% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $2.6B | $-0.7B |
| Year 2 | $3.0B | $-0.5B |
| Year 3 | $3.3B | $-0.3B |
| Year 4 | $3.6B | $-0.0B |
| Year 5 | $4.0B | $0.3B |
What the street says
The August 2026 Phase 3 melanoma success has turned the debate from whether the cancer platform works to how large it can become, and the shares traded around $143 by late August. Moderna joins the Nasdaq-100 on 9 October 2026. Bears still point to a heavily lossmaking respiratory business and the dilution embedded in the new convertible.
Comparable companies: CAH · MCK · COR · HUM · DXCM · MDLN · CNC · INSM
Open the interactive model, price chart and sensitivity grid →